<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722007</url>
  </required_header>
  <id_info>
    <org_study_id>Cormet (P050016) New Enroll</org_study_id>
    <nct_id>NCT00722007</nct_id>
  </id_info>
  <brief_title>Cormet Post-PMA Study: New Enrollment</brief_title>
  <acronym>PASNew</acronym>
  <official_title>Cormet Hip Resurfacing System Post-PMA Study Group (New Enrollment)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the performance of the Cormet Hip
      Resurfacing implant system in the post-approval environment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study tracks the performance of the Cormet Hip Resurfacing system in the post-approval
      environment to see if there are significant changes in device performance from the pre-market
      IDE setting as compared to the post-approval setting. Specifically this study will compare
      the proportion of subjects achieving a Month 24 composite clinical success (CCS) criterion
      and 24 month cumulative revision rate among the newly enrolled post-approval study subjects
      to the IDE subjects' performance on CCS as reported in the Pre-Market Application (PMA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2008</start_date>
  <completion_date type="Actual">May 12, 2014</completion_date>
  <primary_completion_date type="Actual">April 11, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Unilateral Procedures Which Achieved Composite Clinical Success (CCS) at Month 24</measure>
    <time_frame>Month 24+</time_frame>
    <description>Composite Clinical Success (CCS) is based upon the following:
There has been no revision, removal, or replacement of any device component on or prior to the exact 24 month anniversary (i.e., relative day 730); and Month 24 Harris Hip Total score (HHS) ≥ 80 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Implants (Unilateral &amp; Bilateral) With Harris Hip Scores (HHS) Components Including Total, Pain &amp; Function Scored at Month 24+</measure>
    <time_frame>Month 24+</time_frame>
    <description>All unilateral and bilateral implants have been assessed using the following grading:
Total HHS: Excellent (90-100); Good (80-89); Fair (70-79); Poor (&lt;70) Pain HHS: None; Slight; Mild; Moderate; Marked; Totally Disabled Function HHS: Normal (40-47); Mild Dysfunction (30=&lt;39); Moderate Dysfunction (20=&lt;29); Severe Dysfunction (10=&lt;19); Disabled (0=&lt;9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Rate Using Kaplan-Meier Survival Curves</measure>
    <time_frame>Month 24+</time_frame>
    <description>Kaplan-Meier survival curves were completed for all implants (unilateral &amp; bilateral) for Month 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Procedures (Unilateral &amp; Bilateral) With Any Device Related Adverse Events</measure>
    <time_frame>Month 24+</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Procedures (Unilateral &amp; Bilateral) With Any Radiographic Findings at Month 24 Post Operatively</measure>
    <time_frame>Month 24+</time_frame>
    <description>The following was assessed:
Radiolucency Acetabular Component: I; II; III Radiolucency Femoral Component: Superior; Tip; Inferior Cup Migration and Tilt: Superior/Inferior Migration &gt; 4mm; Medial/Lateral Migration &gt; 4mm; Varus/Valgus Tilt &gt; 4 degrees Stem Migration and Tilt: Subsidence of Femoral Component &gt; 4mm and Stem tilting &gt; 4 degrees Other Assessments: Anteversion of the Head ≥ 5mm; Retroversion of the Head ≥ 5 mm; Hypertrophy in Any Zone; Resorption in Any Zone; Lysis in Any Zone; Osteolysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cormet Hip Resurfacing Post-PMA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hip resurfacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cormet Hip Resurfacing</intervention_name>
    <description>Cormet Hip Resurfacing implant</description>
    <arm_group_label>Cormet Hip Resurfacing Post-PMA Group</arm_group_label>
    <other_name>Corin Cormet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient who meets eligibility criteria consistent with product labeling

          -  skeletally mature

          -  mentally capable of completing follow-up forms

          -  Will be available for follow-up out to 2 years and annually thereafter until the last
             patient reaches the two-year evaluation

          -  Has been deemed a candidate for hip replacement by diagnosis of the investigator

          -  consented to participate in the clinical study

        Exclusion Criteria:

          -  Patient with active or suspected infection in or around the hip joint;

          -  Patient with bone stock inadequate to support the device

          -  Patient with severe osteopenia

          -  Patient with a family history of severe osteoporosis or severe osteopenia;

          -  Patient with osteonecrosis or avascular necrosis (AVN) with &gt;50% involvement of the
             femoral head (regardless of FICAT Grade)

          -  Patient with multiple cysts of the femoral head (&gt;1cm)

          -  In cases of questionable bone stock, a DEXA scan may be necessary to assess inadequate
             bone stock.

          -  Patient with any vascular insufficiency, muscular atrophy, or neuromuscular disease
             severe enough to compromise implant stability or postoperative recovery;

          -  Female of child-bearing age due to unknown effects on the fetus of metal ion release.

          -  Patient with known moderate or severe renal insufficiency;

          -  Patient who is immunosuppressed with diseases such as AIDS or person receiving high
             doses of corticosteroids;

          -  Patient who is severely overweight;

          -  Patient with known or suspected metal sensitivity (e.g., jewelry).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Orthopaedic Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lattimore Orthopaedics P.C.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Orthopedic Group LLC</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Bone and Joint Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>November 16, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hip resurfacing</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>avascular necrosis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 24 Apr 2008 and 21 Dec 2011, 147 participants were enrolled in 6 study hospitals, with 160 Cormet resurfacing implants in 134 unilateral and 13 bilateral procedures.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Post-PMA Study</title>
          <description>Implanted with Cormet Hip Resurfacing System after pre-market approval.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cormet Hip Resurfacing Post-PMA Group</title>
          <description>Cormet Resurfacing Hip System implanted after pre-market approval</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Implants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" lower_limit="32" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Unilateral Procedures Which Achieved Composite Clinical Success (CCS) at Month 24</title>
        <description>Composite Clinical Success (CCS) is based upon the following:
There has been no revision, removal, or replacement of any device component on or prior to the exact 24 month anniversary (i.e., relative day 730); and Month 24 Harris Hip Total score (HHS) ≥ 80 points.</description>
        <time_frame>Month 24+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cormet Hip Resurfacing Post-PMA Group</title>
          </group>
        </group_list>
        <measure>
          <title>The Number of Unilateral Procedures Which Achieved Composite Clinical Success (CCS) at Month 24</title>
          <description>Composite Clinical Success (CCS) is based upon the following:
There has been no revision, removal, or replacement of any device component on or prior to the exact 24 month anniversary (i.e., relative day 730); and Month 24 Harris Hip Total score (HHS) ≥ 80 points.</description>
          <units>Implants</units>
          <param>Number</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Implants (Unilateral &amp; Bilateral) With Harris Hip Scores (HHS) Components Including Total, Pain &amp; Function Scored at Month 24+</title>
        <description>All unilateral and bilateral implants have been assessed using the following grading:
Total HHS: Excellent (90-100); Good (80-89); Fair (70-79); Poor (&lt;70) Pain HHS: None; Slight; Mild; Moderate; Marked; Totally Disabled Function HHS: Normal (40-47); Mild Dysfunction (30=&lt;39); Moderate Dysfunction (20=&lt;29); Severe Dysfunction (10=&lt;19); Disabled (0=&lt;9)</description>
        <time_frame>Month 24+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cormet Hip Resurfacing Post-PMA Group</title>
            <description>hip resurfacing
Cormet Hip Resurfacing: Cormet Hip Resurfacing implant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Implants (Unilateral &amp; Bilateral) With Harris Hip Scores (HHS) Components Including Total, Pain &amp; Function Scored at Month 24+</title>
          <description>All unilateral and bilateral implants have been assessed using the following grading:
Total HHS: Excellent (90-100); Good (80-89); Fair (70-79); Poor (&lt;70) Pain HHS: None; Slight; Mild; Moderate; Marked; Totally Disabled Function HHS: Normal (40-47); Mild Dysfunction (30=&lt;39); Moderate Dysfunction (20=&lt;29); Severe Dysfunction (10=&lt;19); Disabled (0=&lt;9)</description>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total HHS Excellent (90-100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HHS Good (80-89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HHS Fair (70-79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HHS Poor (&lt;70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HHS missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS Slight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS Marked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS Totally Disabled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HHS missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function HHS Normal (40-47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function HHS Mild Dysfunction (30=&lt;39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function HHS Moderate Dysfunction (20=&lt;29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function HHS Severe Dysfunction (10=&lt;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function HHS Disabled (0=&lt;9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rate Using Kaplan-Meier Survival Curves</title>
        <description>Kaplan-Meier survival curves were completed for all implants (unilateral &amp; bilateral) for Month 24</description>
        <time_frame>Month 24+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cormet Hip Resurfacing Post-PMA Group</title>
            <description>hip resurfacing
Cormet Hip Resurfacing: Cormet Hip Resurfacing implant</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Rate Using Kaplan-Meier Survival Curves</title>
          <description>Kaplan-Meier survival curves were completed for all implants (unilateral &amp; bilateral) for Month 24</description>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Procedures (Unilateral &amp; Bilateral) With Any Device Related Adverse Events</title>
        <time_frame>Month 24+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cormet Hip Resurfacing Post-PMA Group</title>
            <description>hip resurfacing
Cormet Hip Resurfacing: Cormet Hip Resurfacing implant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Procedures (Unilateral &amp; Bilateral) With Any Device Related Adverse Events</title>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Procedures (Unilateral &amp; Bilateral) With Any Radiographic Findings at Month 24 Post Operatively</title>
        <description>The following was assessed:
Radiolucency Acetabular Component: I; II; III Radiolucency Femoral Component: Superior; Tip; Inferior Cup Migration and Tilt: Superior/Inferior Migration &gt; 4mm; Medial/Lateral Migration &gt; 4mm; Varus/Valgus Tilt &gt; 4 degrees Stem Migration and Tilt: Subsidence of Femoral Component &gt; 4mm and Stem tilting &gt; 4 degrees Other Assessments: Anteversion of the Head ≥ 5mm; Retroversion of the Head ≥ 5 mm; Hypertrophy in Any Zone; Resorption in Any Zone; Lysis in Any Zone; Osteolysis</description>
        <time_frame>Month 24+</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cormet Hip Resurfacing Post-PMA Group</title>
            <description>hip resurfacing
Cormet Hip Resurfacing: Cormet Hip Resurfacing implant</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Procedures (Unilateral &amp; Bilateral) With Any Radiographic Findings at Month 24 Post Operatively</title>
          <description>The following was assessed:
Radiolucency Acetabular Component: I; II; III Radiolucency Femoral Component: Superior; Tip; Inferior Cup Migration and Tilt: Superior/Inferior Migration &gt; 4mm; Medial/Lateral Migration &gt; 4mm; Varus/Valgus Tilt &gt; 4 degrees Stem Migration and Tilt: Subsidence of Femoral Component &gt; 4mm and Stem tilting &gt; 4 degrees Other Assessments: Anteversion of the Head ≥ 5mm; Retroversion of the Head ≥ 5 mm; Hypertrophy in Any Zone; Resorption in Any Zone; Lysis in Any Zone; Osteolysis</description>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Radiolucency Acetabular Component - I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiolucency Acetabular Component - II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiolucency Acetabular Component - III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiolucency Femoral Component - Superior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiolucency Femoral Component - Tip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiolucency Femoral Component - Inferior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superior/Inferior Cup Migration &gt; 4mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial/Lateral Cup Migration &gt; 4mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varus/Valgus Cup Tilt &gt; 4 degrees</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stem subsidence of &gt; 4mm and stem tilt of &gt; 4°</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anteversion of the Head ≥ 5mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retroversion of the Head ≥ 5 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertrophy in Any Zone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resorption in Any Zone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysis in Any Zone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cormet Hip Resurfacing Post-PMA Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Deep joint infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hip pseudotumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Acetabular loosening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral hip resurfacing</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral revision THR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral revision TKR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral THR</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral TKA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Femoral loosening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hip dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hamstring detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hip pain (operative side)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Meniscus tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contralateral hip pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Contralateral OA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hip pain (operative side)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Iliopsoas tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>IT band friction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>L5-S1 spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor will review publications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. If the sponsor determines the publication contains patentable subject matter the embargo can be extended up to 120 days from the time submitted to the sponsor for review. The PI shall agree to accept the sponsor's reasonable comments and suggestions with respect to publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lucinda Gerber</name_or_title>
      <organization>Corin USA Limited</organization>
      <phone>(772) 321 2478</phone>
      <email>lucinda.gerber@coringroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

